Harvard chair of Biostatistics and pioneer of computational biology joins PGxAI’s advisory team

PGxAI is delighted to announce that John Quackenbush, PhD—Professor of Computational Biology & Bioinformatics in the Department of Biostatistics at the Harvard T.H. Chan School of Public Health—has joined the company's Scientific Advisory Board. Dr Quackenbush also holds faculty appointments in the Channing Division of Network Medicine of Brigham and Women’s Hospital and at the Dana-Farber Cancer Institute.

Over a career that began with a PhD in theoretical physics (UCLA) and shifted to the Human Genome Project in 1992, Dr Quackenbush has become a leading voice in systems and computational biology. He has authored 350+ peer-reviewed papers cited more than 103,000 times and created widely used software for network medicine and systems biology. His work involves integrating massive multi-omics datasets to reveal how subtle, combinatorial effects drive human health and disease.

Dr Quackenbush’s impact extends well beyond academia:

• White House Open Science “Champion of Change” (2013) for making large‐scale genomic data broadly accessible.
• Election to the U.S. National Academy of Medicine (2022) for pioneering reproducible, network-based approaches to precision medicine.
• Entrepreneurship: Co-founded Genospace in 2011, a cloud platform for precision-medicine analytics; merged with HCA’s Sarah Cannon in 2017 and was acquired by McKesson in 2022 to power its oncology data strategy.

At PGxAI, Dr Quackenbush will guide the expansion of our multi-omics integration pipeline, promote rigorous reproducibility standards, and help align our AI-driven pharmacogenomic insights with national health-IT interoperability frameworks—accelerating our mission to deliver truly personalized therapy at scale.

“We are honored to welcome Dr. John Quackenbush to PGxAI’s Scientific Advisory Board. His groundbreaking work in computational biology and systems genomics has advanced precision medicine worldwide. His perspective will help transform genomic insights into meaningful improvements for patients’ lives.” — Mike Zack, PhD, MD, CEO & Co-Founder, PGxAI

“I am excited to join the SAB at PGxAI as they chart a course to bring cutting-edge, results-driven AI systems to address some of the most challenging problems in health care. Their innovative strategy provides positions them well to have a substantial impact.” — John Quackenbush, PhD.